<DOC>
	<DOCNO>NCT00114517</DOCNO>
	<brief_summary>The purpose study examine effect oral 17B-estradiol ( estrogen ) progression early ( subclinical ) atherosclerosis cognitive decline healthy postmenopausal woman .</brief_summary>
	<brief_title>ELITE : Early Versus Late Intervention Trial With Estradiol</brief_title>
	<detailed_description>The primary hypothesis test 17B-estradiol ( estrogen ) reduce progression early atherosclerosis initiate soon menopause vascular endothelium ( line blood vessel ) relatively healthy versus later endothelium lose responsiveness estrogen . Ultrasonography use measure rate change thickness carotid artery cardiac compute tomography ( CT ) use measure coronary artery calcium coronary artery lesion . The second hypothesis test 17B-estradiol ( estrogen ) reduce progression cognitive decline initiate soon menopause healthy brain tissue remain responsive estrogen versus later brain tissue lose responsiveness estrogen . A total 643 ( actual ) ( 504 , initially propose ) postmenopausal woman randomize accord number year since menopause , less 6 year 10 year , receive either oral 17B-estradiol 1 mg daily placebo . Women uterus also use vaginal progesterone gel 4 % ( placebo gel ) last ten day month . The vaginal progesterone distribute double-blind fashion along randomized treatment woman expose active treatment receive active progesterone . As initially propose , participant undergo ultrasonography baseline every 6 month throughout 2 5 year ( average 3 year ) randomize treatment . Participants also undergo cognitive test baseline 3 year randomize treatment . The trial extend additional 2 2.5 year randomize treatment ( overall average randomize treatment 5 year range 2 8.5 year ) . Ultrasonography continue collect every 6 month upon completion randomize treatment , participant undergo cardiac CT coronary artery calcium coronary artery lesion measurement . Participants also undergo third cognitive test completion randomize treatment .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Women serum estradiol level 25 pg/ml less No period 6 month Postmenopausal le 6 year , OR 10 year longer Clinical sign , symptom , personal history cardiovascular disease Women hysterectomy oophorectomy ( since time menopause determine ) Diabetes mellitus fast serum glucose 140 mg/dL great Uncontrolled hypertension ( diastolic blood pressure 110 mmHg great ) Thyroid disease ( untreated ) Serum creatinine great 2.0 mg/dL Plasma triglyceride level great 500 mg/dL Life threaten disease prognosis le 5 year Cirrhosis liver disease History deep vein thrombosis pulmonary embolism History breast cancer Current hormone replacement therapy ( HRT )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>CAD</keyword>
	<keyword>cardiac compute tomography</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>carotid artery intima-media thickness</keyword>
	<keyword>cognitive function</keyword>
	<keyword>compute tomography</keyword>
	<keyword>coronary artery calcium</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>coronary artery lesion</keyword>
	<keyword>CVD</keyword>
	<keyword>estrogen</keyword>
	<keyword>estrogen therapy</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>subclinical vascular disease</keyword>
	<keyword>time hypothesis</keyword>
	<keyword>ultrasonography</keyword>
</DOC>